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Abstract: The active targeting to alveolar macrophages (AM) is an attractive strategy to improve the
therapeutic efficacy of ‘old’ drugs currently used in clinical practice for the treatment of pulmonary
tuberculosis. Previous studies highlighted the ability of respirable solid lipid nanoparticle assemblies
(SLNas), loaded with rifampicin (RIF) and functionalized with a novel synthesized mannose-based
surfactant (MS), both alone and in a blend with sodium taurocholate, to efficiently target the AM
via mannose receptor-mediated mechanism. Here, we present the in vivo biodistribution of these
mannosylated SLNas, in comparison with the behavior of both non-functionalized SLNas and bare
RIF. SLNas biodistribution was assessed, after intratracheal instillation in mice, by whole-body
real-time fluorescence imaging in living animals and RIF quantification in excised organs and plasma.
Additionally, SLNas cell uptake was determined by using fluorescence microscopy on AM from
bronchoalveolar lavage fluid and alveolar epithelium from lung dissections. Finally, histopathological
evaluation was performed on lungs 24 h after administration. SLNas functionalized with MS alone
generated the highest retention in lungs associated with a poor spreading in extra-pulmonary regions.
This effect could be probably due to a greater AM phagocytosis with respect to SLNas devoid of
mannose on their surface. The results obtained pointed out the unique ability of the nanoparticle
surface decoration to provide a potential more efficient treatment restricted to the lungs where the
primary tuberculosis infection is located.
Keywords: tuberculosis; in vivo administration; lipid nanoparticles; alveolar macrophages;
active targeting
1. Introduction
Priorities to achieve the WHO goal of ending tuberculosis (TB) epidemic by 2030 include new
drugs or formulation approaches to simplify and shorter conventional drug regimens [1]. TB is
caused by Mycobacterium tuberculosis (Mtb) residing and surviving inside alveolar macrophages (AM).
After being inhaled, Mtb reaches the alveoli, where it is phagocytosed by AM, a site difficult to be
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reached effectively by most antibiotics [2–6]. If the primary infection (pulmonary TB) is not completely
eradicated, it can progress and disseminate into other organs (miliary TB). It is important to point out
that conventional administration routes, such as oral or parenteral, may lead to sub-therapeutic levels of
anti-TB drugs at the primary site of infection, due to poor pulmonary distribution of most systemically
administered drugs. As a result, drug-resistant strains may appear quickly [7]. Considering that 75–80%
of infection cases remain localized in the lungs, the pulmonary route, widely used for local or systemic
treatment of other pathologies [8], appears to be the most promising route of drug administration
to reach promptly AM, the primary site of Mtb infection [9,10]. Local administration could harbor
resistant tubercle bacilli and avoid first-pass metabolism and gastrointestinal degradation, leading to a
reduction in dose level and preventing adverse drug reactions.
With the purpose to confer on drugs alone the properties required for a powder inhalation therapy
in terms of respirability and internalization by AM, particulate vehicles have gained extensive attention.
Among these, lipid-based particles are composed of lipids generally recognized as safe and devoid of
toxicity following pulmonary administration for most of them [11,12]. Thus, these carriers represent
a useful approach for the administration of drugs against pulmonary TB, enabling their deposition
onto alveolar epithelia and transport into AM after drug emission by dry powder inhaler devices.
Concerning the mechanism of AM entry, phagocytosis is the established mechanism for particles in the
range of about 1–3 µm, preserved in macrophages infected by Mtb, providing efficient intracellular
drug delivery after only 1 h [4,13,14]. In addition, drug biological activity inside infected AM can be
reasonably expected owing to the intracellular biodegradation of the lipid matrix [15].
Within this context, we previously developed respirable solid lipid nanoparticle assemblies (SLNas)
loaded with rifampicin (RIF), a clinically useful first-line anti-TB drug, for an AM passive targeting [6,16].
Thereafter an AM active targeting to mannose receptors (MR), located on the macrophage membrane
and overexpressed in case of Mtb-infection, was obtained by exploiting mannosylated SLNas. To
achieve this, SLNas were surface-decorated with a newly synthesized mannosylated derivative acting
as both surfactant, required for the nanoparticle production, and functionalized agent for the AM active
targeting. The mannosylated SLNas demonstrated their ability to interact with MR on J774 and MH-S
macrophage cell lines improving cell internalization ability in comparison with non-functionalized
SLNas and bare RIF. Furthermore, the MR-specific binding was negligibly impaired by the protein/lipid
corona layer formed around the nanoparticles upon their contact with a commercial substitute of the
natural pulmonary surfactant [6,17].
In addition to AM phagocytosis, other pathways should be considered before establishing a
targeting to the alveolar region. Indeed, a few in vivo examples of translocation across the alveolar
epithelium through the interstitium into the blood or lymphatic circulation were reported [18–22],
even if the mechanism involving inhaled nanoparticle alveolar clearance remains quite unknown. It
therefore follows that in vivo experimental studies have to be performed to assess the actual fate of
inhaled particles, especially for those having new surface physicochemical properties.
Thus, the purpose of the present work was to detect in mouse lungs and extra-pulmonary organs
the biodistribution of the previously developed SLNas surface-decorated with the mannose surfactant
in comparison with non-functionalized samples and bare RIF.
2. Materials and Methods
2.1. Materials
Palmitic acid (PA) was purchased from Fluka Chemie (Buchs, Switzerland), cholesteryl myristate
(CM) from TCI Europe (Zwijndrecht, Belgium), polyoxyethylene–polyoxypropylene block copolymer
(Lutrol F127) (F127) from BASF (Ludwigshafen, Germany), sodium taurocholate (ST), rifampicin
(RIF) from Alfa Aesar (Ward Hill, MA, USA), IR-780 iodide from Sigma-Aldrich (Milan, Italy),
and RPMI 1640 from PAN-Biotech (Aidenbach, Germany). The mannose derivative hexadecanoic acid
(aminoethyl α-D-mannopyranoside) amide (MS) was synthesized as previously reported [6] and used
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as mannosylated functionalizing/surfactant agent. For HPLC analysis, methyl parahydroxybenzoate,
used as internal standard (IS), was purchased from Carlo Erba Reagenti (Milan, Italy). For the in vivo
experiments, ketamine and xylazine were purchased from Syntec (Santana de Parnaiba, São Paulo,
Brazil), hematoxylin–eosin (H&E) from Easypath (Indaiatuba, São Paulo, Brazil), ascorbic acid from
Merck (São Paulo, Brazil), Hoechst 33,342 from Invitrogen (Carlsbad, CA, USA), and Tissue-Tek
O.C.T. Compound from Sakura (Alphen aan den Rijn, Netherlands). All the other chemicals were of
analytical grade.
2.2. SLNas Preparation
SLNas were prepared by the melt emulsification technique, as previously described in detail [17].
Briefly, the lipid phase containing 92.5 mg PA, 42.5 mg CM, and 45 mg RIF was melted and emulsified
by ultrasonication (Branson Sonifier® SFX150, Emerson, St. Louis, MO, USA) (input 150 W for 3
min) in 10 mL MilliQ water containing the surfactant/functionalizing agent MS (0.1%) alone or in a
blend with ST (0.05%) to prepare SLNas/MS or SLNas/MS-ST samples, respectively. As the controls,
non-mannosylated SLNas/ST and SLNas/F127 samples were obtained by using 0.2% ST or 1% F127,
respectively, as emulsifier. After cooling in ice bath, SLNas samples were purified by dialysis, frozen
at −70 ◦C, and freeze-dried (Lio 5P, CinquePascal, Milan, Italy) according to the method previously
adopted [23]. All the samples were used in a labeled form by dissolving preventively 0.2% IR-780 in
the melted PA before the melt emulsification process.
2.3. Morphology, Size, and Z-Potential
SLNas morphology was evaluated by Scanning Electron Microscopy (SEM, Nova NanoSEM 450,
Fei, Eindhoven, The Netherlands) using TEM mode with STEM detector (30 kV) on SLNas coated
with carbon (carbon coater, Balzers CED- 010, Oerlikon Balzers, Liechtestein). Photon Correlation
Spectroscopy (PCS) (Zetasizer version 6.12, Malvern Instruments, Worcs, U.K.) equipped with a 4 mW
He-Ne laser (633 nm) and a DTS software (Version 5.0) was used to measure size, polydispersity index
(PDI), and Z-potential values. Before the test, all the samples were suspended in MilliQ water for
Z-potential analyses or RPMI 1640 medium for size and PDI determination, vortexed for 1 min and
dispersed for 3 min in ultrasonic bath (USC200TH, VWR International, Milan, Italy) at 37 ◦C. Each
sample was analyzed in triplicate.
2.4. HPLC Analysis
Quantification of RIF in both mice organs and SLNas samples was carried out using a 1260 Infinity
HPLC (Agilent Technologies, Santa Clara, CA, USA) equipped with a 1260 quaternary pump, 1260
DAD detector, and 1260 ALS flow cell. Chromatographic separation was achieved using a Zorbax
Extend C18 column (150 × 4.6 mm, 5 µm) (Agilent Technologies) at 35 ◦C. The mobile-phase consisted
of a mixture of acetonitrile (ACN):water (v/v) with flow rate of 1.0 mL/min and used in a gradient as
follows: 30:70 until 2 min, increasing to 70:30 at 2–4 min, kept at 70:30 until 7 min, decreasing to 30:70
from 7–9 min and kept at 30:70 until 11 min. Detection wavelengths were 254 nm and 333 nm (for
plasma samples) and the injection volume was 10 µL. For the drug loading determination, a calibration
curve from 5 to 30 µg/mL was obtained with r2 > 0.995. Calibration curves in each organ were obtained
from 0.09 to 2.7 µg/mL and from 3 to 7 µg/mL with r2 > 0.988, using IS. Run time was 11 min, and RIF
elution was observed at 5.4 min and IS elution at 3.7 min.
2.5. Drug Loading Levels
To 10 mg of SLNas samples, 10 mL of IS solution and methanol were added. The suspension
was heated at 50 ◦C for 30 min, properly diluted (1:5) with methanol, filtered, and analyzed by HPLC.
Drug loading (DL%) was calculated as the weight percentage of RIF in the total particle weight. The
reported values were averaged on three determinations.
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2.6. In Vitro Release
In vitro RIF dissolution and release from SLNas powders were examined in sink conditions
on exactly weighed samples (100 mg) by means of the dialysis membrane (MWCO 12–14,000 Da;
Medicell International Ltd., London, GB) method, in 30 mL of simulated lung fluid (SLF) according to
Marques [24] under gently magnetic stirring at the temperature of 37.0 ± 0.2 ◦C to reproduce stagnant
lung conditions. Sample solutions (1 mL) were withdrawn at fixed intervals for a time period of 6 h
and the initial volume restored. RIF quantification was performed spectrophotometrically (Lambda 35;
Perkin-Elmer, Norwalk, CT, USA) at the wavelength of 475 nm. Sample solutions were also monitored
for IR-780 release from SLNas by spectrophotometric quantification at the wavelength of 783 nm. The
reported values were averaged on three determinations.
2.7. In Vivo Study
2.7.1. Animals
Female Swiss mice aged 4–6 weeks (27–35 g) were obtained from the Central Animal Facility at
Federal University of Goiás (Goiânia, Goiás, Brazil). Considering the preliminary study phase, healthy
animals were used. Animals were acclimatized for a week prior to the beginning of experiments
under 12:12 h light–dark cycles and controlled temperature. Food and water were provided ad libitum
and animals were treated with chlorophyll-free grains for 7 days before treatment. Experiments
were conducted according to the NC3RS guidelines for laboratory animal care. The experimental
protocol (no. 109/18) was approved by the Animal Research Ethics Committee of the Federal University
of Goiás. Animals were anesthetized before sample administration with ketamine and xylazine
at 100 and 10 mg/kg, respectively. The powder aerosolization followed the method described by
Chaurasiya et al. [25]. Briefly, after intubation, 3 × 350 µL puffs of air were used to administer the
powders into the mouse trachea using 20 GA × 1.16” catheters connected to 1 mL syringe.
2.7.2. Real-Time Fluorescence Imaging
Four groups of mice (n = 4 per group) were treated with 3 mg of SLNas/MS, SLNas/MS-ST,
SLNas/ST, and SLNas/F127 formulations. An untreated group was used as the control. Real-time
fluorescence imaging was used to evaluate qualitatively the tissue distribution of SLNas formulations.
Fluorescence scans were performed at 0.5, 3, 6, and 24 h after administration using a fluorescence
molecular tomography (FMT) in vivo imaging system (model 1500, Perkin-Elmer, Norwalk, CT, USA).
Excitation and emission quantification wavelengths were 790 nm and 780 nm. Animals were euthanized
24 h after treatment using an excess of anesthetic. Lungs, heart, liver, and kidneys were harvested,
rinsed with 0.9% NaCl solution and imaged for fluorescence detection by FMT.
2.7.3. Lung Section Analysis
At 24 h after intratracheal administration of SLNas samples, lungs were dissected and flash-frozen
with liquid nitrogen in Tissue-Tek O.C.T. Compound. Transverse sections of 6 µm thickness were
obtained at various points along the length of the tissue (superior, median, and caudal regions) using
a Leica CM-1850 cryostat (Leica Biosystems, Inc., Buffalo Grove, IL, USA). For histopathological
evaluation, the sections were stained with H&E and analyzed using light microscopy (DM 2000 Leica
Microsystems, Bannockburn, IL, USA) coupled to a photographic camera (Canon PowerShot S80,
VA, USA). Moreover, lung sections were observed by fluorescence microscopy (DMI 4000B, Leica
Microsystems, Bannockburn, IL, USA).
2.7.4. Rifampicin Biodistribution
To quantify the amount of RIF in the different tissues after intratracheal administration, mice
were randomly divided into five groups (n = 4–6 per group) and treated with 3 mg of SLNas/MS,
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SLNas/MS-ST, SLNas/ST, and SLNas/F127 or bare RIF diluted with 3 mg of mannitol (10% RIF) to
obtain insufflation RIF dose comparable to those of SLNas samples. An untreated group was used as
the control. Mice were euthanized 30 min and 3 h after treatment.
2.7.5. Actual Inhaled Drug Dose
The non-administered SLNas powder was quantified in order to calculate the actual inhaled
dose of RIF per mouse. In practice, each administration device was washed 10× with 2 mL of
ACN containing IS. The resulted suspension was heated at 50 ◦C for 30 min and filtered (0.45 µm
porosity). The obtained solution was analyzed by HPLC. The inhaled dose, expressed as percentage
of the administered one, was calculated by subtracting the non-administered powder to the amount
introduced into the administration device.
2.7.6. Bronchoalveolar Lavage Fluid
Bronchoalveolar lavage fluid (BALF) was collected as described by Aragao-Santiago [26]. Alveolar
macrophages were separated from the BALF by centrifugation at 500× g for 10 min. The cell pellet was
then split in two aliquots for AM fluorescence microscopy and RIF quantification. For fluorescence
microscopy, BALF cells were smeared in duplicates onto slides using Cyto-System (Hettich, Germany)
at 219 g for 10 min, at room temperature. Cytoslides were then stained with Hoechst 33,342 and
observed using fluorescence microscopy. For RIF quantification, cells were lysed by the addition of
200 µL ACN containing IS and sonicated by ultrasonic bath for 15 min. The solutions were filtered
(0.45 µm porosity) and analyzed.
2.7.7. Plasma and Organs
Blood was collected by cardiac puncture and immediately centrifuged at 2000× g for 5 min to
separate the plasma, which was stored overnight at −70 ◦C before analysis by HPLC. Lungs, liver,
and kidneys were harvested, rinsed with 0.9% NaCl, dried, and weighed. Tissues were homogenized
in pH 4.5 phosphate-buffered saline (PBS), containing 10−3 M of ascorbic acid, by Ultra-Turrax (Ika
Labortechnik, Staufen, Germany) at 20,000 rpm for 3 min in glass conical tubes placed in ice. The
homogenates were stored at −70 ◦C overnight prior to HPLC analysis. RIF was extracted from tissues
and plasma by protein precipitation. 300 µL of homogenate and 150 µL of plasma were treated with
1 mL and 500 µL of ACN (4 ◦C), respectively, and mixed by vortex for 60 s. The mixtures were
centrifuged at 5000× g for 5 min (4 ◦C). The supernatants were collected, filtered (0.45 µm porosity),
and analyzed. The IS, diluted with ACN, was added to all samples to a final concentration of 0.69 µg/mL
prior to protein precipitation.
2.8. Statistical Analysis
Statistical analysis of data was performed by two-way analysis of variance (ANOVA) followed by
Bonferroni’s test. Differences between groups were considered to be statistically significant at p < 0.05.
3. Results and Discussion
In our previous works, respirable mannosylated SLNas/MS and SLNas/MS-ST samples were
designed to exploit the benefit of an active targeting via mannose receptor-mediated mechanism on
AM internalization ability. Mannosylation was achieved by anchoring on SLNas surface a newly
synthesized mannose surfactant (MS) alone or in a blend with sodium taurocholate (ST). Indeed,
mannose derivatives show selectivity for multiple C-type lectin-like domains on mannose receptor
(MR) whereas ST was selected for its absorption enhancing ability as well as a possible recognition of the
N-terminal cysteine-rich domain on MR [27]. Non-mannosylated SLNas/ST and SLNas/F127, produced,
respectively, by using ST alone and F127 that does not bear groups able to bind MR, were investigated
as the controls. The samples were characterized for particle geometrical properties, flowability, physical
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state, wettability, respirability performance, mannosylation efficacy, and protein/lipid corona formation.
Moreover, cytotoxicity, actual MR involvement, and RIF transport within alveolar macrophage MH-S
cell line, also in the presence of a pulmonary surfactant substitute, were assessed. The mannosylated
samples satisfied the properties required for reaching the alveolar epithelium in terms of respirability
parameters. Moreover, the functionalization by means of mannose groups, in particular on SLNas/MS
surface, improved RIF translocation into MH-S cells without impairment caused by the corona layer
covering the nanoparticles [17].
3.1. In Vitro Properties
The present investigation was carried out to establish in vivo RIF biodistribution following
intratracheal administration in mice of SLNas/MS and SLNas/MS-ST samples in comparison with the
controls SLNas/ST and SLNas/F127. The samples were used in their labeled state by means of IR-780
dye. Consequently, the same batch of each SLNas sample to be administered to mice was analyzed to
verify morphology, size, Z-potential, drug loading, and in vitro release in SLF.
All the SLNas samples appeared mainly as aggregates of smaller nanoparticles (Figure 1). These
assemblies were rounded in shape with a size of the main class (>85%) in the range from 450 nm
to 850 nm and DPI values from 0.41 to 0.71 owing to the presence of minor populations (<15%).
Z-potential values of the samples were from −8.5 to −55 mV. The most negative values were due to
MS and ST charges whereas the lowest magnitude was conferred by the non-ionic F127 (p < 0.05).
Rifampicin payload in SLNas was about 10% without relevant differences among the samples (Table 1).
Nanomaterials 2020, 10, x FOR PEER REVIEW 6 of 15 
 
protein/lipid corona formation. Moreover, cytotoxicity, actual MR involvement, and RIF transport 
within alveolar macrophage MH-S cell line, also in the presence of a pulmonary surfactant substitute, 
were assessed. The mannosylated samples satisfied the properties required for reaching the alveolar 
epithelium in terms of respirability parameters. Moreover, the functionalization by means of 
mannose groups, in particular on SLNas/MS surface, improved RIF translocation into MH-S cells 
without impairment caused by the corona layer covering the nanoparticles [17]. 
3.1. In Vitro Properties 
The present investigation was carried out to establish in vivo RIF biodistribution following 
intratracheal administration in mice of SLNas/MS and SLNas/MS-ST samples in comparison with the 
controls SLNas/ST and SLNas/F127. The samples were used in their labeled state by means of IR-780 
dye. Consequently, the same batch of each SLNas sample to be administered to mice was analyzed 
to verify morphology, size, Z-potential, drug loading, and in vitro release in SLF. 
All the SLNas samples appeared mainly as aggregates of smaller nanoparticles (Figure 1). These 
assemblies were rounded in shape with a size of the main class (>85%) in the range from 450 nm to 
850 nm and DPI values from 0.41 to 0.71 owing to the presence of minor populations (<15%). Z-
potential values of the samples were from −8.5 to −55 mV. The most negative values were due to MS 
and ST charges whereas the lowest magnitude was conferred by the non-ionic F127 (p < 0.05). 
Rifampicin payload in SLNas was about 10% without relevant differences among the samples (Table 
1). 
 
Figure 1. SLNas images by transmission electron microscopy. 
Table 1. Size, PDI, Z-potential, and drug loading levels of the SLNas samples (mean values ± SD) 
 SLNas/MS SLNas/MS-ST SLNas/ST SLNas/F127 
Size (nm) 559 ± 113 452 ± 92 520 ± 11 855 ± 97 
PDI 0.68 ± 0.10 0.41 ± 0.02 0.56 ± 0.03 0.71 ± 0.06 
Z-potential (mV) −43.1 ± 1.6 −39.4 ± 1.9 −54.6 ± 2.2 −8.5 ± 0.3 
Drug loading (%, w/w) 9.6 ± 0.2 10.3 ± 0.4 11.8 ± 0.4 8.10 ± 0.1 
Concerning in vitro release, which allows for predicting drug leaching before AM 
internalization, RIF release profile from SLNas was gradual compared with the fast and complete 
free RIF dissolution. About 30% RIF was released from mannosylated SLNas/MS and SLNas/MS-ST 
at the end of the experiment, less than the values detected from the non-mannosylated samples 
(Figure 2), probably owing to a stronger barrier offered by the mannosylated surfactant [6]. In the 
light of the fast internalization process by AM, acceptable drug retaining within SLNas matrices 
Figure 1. SLNas images by transmission electron microscopy.
Table 1. Size, PDI, Z-potential, and drug loading levels of the SLNas samples (mean values ± SD)
SLNas/MS SLNas/MS-ST SLNas/ST SLNas/F127
Size (nm) 559 ± 113 452 ± 92 520 ± 11 855 ± 97
PDI 0.68 ± 0.10 0.41 ± 0.02 0.56 ± 0.03 0.71 ± 0.06
Z-potential (mV) −43.1 ± 1.6 −39.4 ± 1.9 −54.6 ± 2.2 −8.5 ± 0.3
Drug loading (%, w/w) 9.6 ± 0.2 10.3 ± 0.4 11.8 ± 0.4 8.10 ± 0.1
Concerning in vitro release, which allows for predicting drug leaching before AM internalization,
RIF release profile from SLNas was gradual compared with the fast and complete free RIF dissolution.
About 30% RIF was released from mannosylated SLNas/MS and SLNas/MS-ST at the end of the
experiment, less than the values detected from the non-mannosylated samples (Figure 2), probably
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owing to a stronger barrier offered by the mannosylated surfactant [6]. In the light of the fast
internalization process by AM, acceptable drug retaining within SLNas matrices before macrophage
uptake would be therefore reasonably expected. IR-780 was not registered in the release medium
throughout the experiment.
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3.2. In Vivo Study
The transport of RIF within pulmonary and extra-pulmonary regions by means of mannosylated
SLNas (SLNas/MS and SLNas/MS-ST) was assessed in mice following intratracheal administration of
3 mg dose of powder, i.e., the maximum tolerated dose. The study involved the real-time whole-body
imaging on living mice and excised organs (lungs, liver, and kidneys) as well as the fluorescence
microscopy of AM from BALF and lung dissections. Additionally, RIF was quantified in AM, lungs,
plasma, liver, and kidneys. Liver and kidneys were selected as extra-pulmonary organs for their
relevance in RIF systemic pathway, accumulation, and metabolism. Drug transport was compared
with that provided by administering non-mannosylated SLNas (SLNas/ST and SLNas/F127) and bare
RIF. Short-term studies were performed at quantification times of 0.5 h and 3 h post-exposure since
AM internalization as well as pulmonary and extra-pulmonary effects occurs within the first hours
after administration [28–30].
FMT performed on mice and fluorescence microscopy on AM collected from BALF exploited the
fluorescence emitted from IR-780 retained within SLNas, as demonstrated by the in vitro release study.
Indeed, the highly hydrophobic nature of this dye allowed its firm non-covalent embedding in several
lipid structures [31,32].
Concerning RIF determination, data generating from each animal in terms of drug concentration
were related to the drug loading corresponding to each administered sample. Moreover, since
relationships between dosage emission and device flow-rate are well known [33–35], the actual inhaled
dose per mouse was calculated by considering RIF amount not emitted by the device. The actual
emission doses were ≥70% of those loaded inside the device (78.6 ± 3.3%, 69.3 ± 9.2%, 85.6 ± 5.4%,
for SLNas/MS, SLNas/MS-ST, SLNas/ST, respectively) apart from SLNas/F127 with an emission dose
of 53.4 ± 10.7% owing to its very poor flowability and high cohesiveness already highlighted in our
previous work [17].
3.2.1. Fluorescence Imaging on Mice Whole-Body and Excised Organs
SLNas accumulation and retention within lungs after intratracheal administration was assessed by
real-time FMT. The analysis was carried out for 24 h in order to monitor particle permanence in lungs
and particle spreading to all body, by measuring IR-780 fluorescence intensity emitted from living mice
whole-bodies. Moreover, excised organs (lungs, liver, and kidneys) were analyzed 24 h post-exposure.
Taking into account nanoparticle ability to penetrate into rodent lung interstitial spaces [36], SLNas
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detection in lungs was assigned to both particle translocation across epithelial cells and internalization
by AM which were not removed by BALF.
Despite IR-780 strong fluorescence intensity and low fluorescent mice diet used in the present
study, mice auto-fluorescence limited the monitoring of SLNas distribution by means of FMT [37].
Nevertheless, increases in IR-780 accumulation compared with the fluorescence from untreated animals
were registered only in the lungs of SLNas/MS-treated mice. Concerning mice organs excised at
24 h, fluorescence was registered only in the lungs, regardless of SLNas sample, even though a
higher intensity was observed after SLNas/MS administration (Figure 3). This finding may offer a
preliminary evidence of a more substantial translocation and long-term accumulation within lungs
of the nanoparticles surface-decorated only with MS as compared with the other SLNas samples.
Appreciable IR-780 emissions from extra-pulmonary regions were not detected, regardless of SLNas
sample, demonstrating the high retention of SLNas in the pulmonary region with a poor diffusion in
the circulatory system.
Nanomaterials 2020, 10, x FOR PEER REVIEW 8 of 15 
 
Despite IR-780 strong fluorescence intensity and low fluorescent mice diet used in the present 
study, mice a to-fluorescence limited the moni oring of SLNas distribution by means of FMT [37]. 
Nevertheless, incr ases in IR-780 accumulation compared with the fluorescence from untreated 
animals wer  registered only in the lu gs of SLNas/MS-treated mice. Concerning mic  organs exci d 
at 24 h, fluorescence wa  registered only in the lungs, regardle s of SLNas sample, even though a 
high r inten ity was observed after SLN s/MS administration (Figu  3). This findi g may offer a 
pr liminary evi ence of a more substantial translocation and long-term accu ulation within lungs 
of t e nanoparticl s surface-d corated only with MS as compared with the other SLNas samples. 
Appr ciabl  IR-780 emis ions from extra-pulmonary regions were not detected, regardless of SLNas 
sample, demonstrating the high reten ion of SLNas in he pulmonary region with a p or d ffusion in 
the circulat ry syst m.  
Finally, no IR-780 ignal was found in the upp r respiratory region at all scanning times, 
suggesting the nanopar icle deposition into the lower respirat ry tract, without any mucociliary 
clearan e.  
 
Figure 3. Representative FMT images at 0.5, 3, 6, and 24 h after administration of SLNas to mice. 
Whole-body scans were acquired after pulmonary treatment of SLNas/MS, SLNas/MS-ST, SLNas/ST, 
and SLNas/F127 samples. Images of the excised organs (lungs, liver, and kidneys from top down) 
show the organ biodistribution of particle-related fluorescence at 24 h post-exposure. 
3.2.2. SLNas Biodistribution in the Pulmonary Region 
In order to further investigate the localization and permanence of SLNas samples within the 
pulmonary region, fluorescence microscopy on AM from BALF and lung tissue sections was 
performed. Subsequently, RIF quantification in both AM and lung tissue was investigated. Once 
nanoparticles are deposited onto the alveolar region of the respiratory tract, they first come into 
contact with pulmonary surfactant and then they are taken up by AM mostly within 2–3 h after 
particle deposition [19]. Hence, BALF was isolated in order to remove non-internalized nanoparticles 
from the lungs and collect non-adherent AM, i.e., the cells residing in the airway lumen and 
representing more than 90% of the cells contained in the mouse BALF [38–40]. As a further result, 
non-adherent AM were separated from interstitial macrophages, a large component of the total 
macrophage population in murine lungs residing in lung parenchyma [41]. AM recovery from BALF, 
however, has been reported to be incomplete since the most activated AM by particle internalization 
strongly adhere to the lung tissue [41,42]. The morphologic study of BALF cell population by optical 
Figure 3. Representative FMT images at 0.5, 3, 6, and 24 h after administration of SLNas to mice.
Whole-body scans wer acquired after pulmonary treatment of SLNas/MS, SLNas/MS-ST, SLNas/ST,
and SLNas/F127 amples. Images of the excised organs (lungs, liver, nd kidneys from top down) show
the organ biodistribution of particle-relat d fluorescence at 24 h post-exposure.
Finally, no IR-780 signal was found in the upper respiratory region at all scanning times, suggesting
the nanoparticle depositi i to the lower respirat ry tract, without any mucociliary clearance.
3.2.2. SLNas Biodistribution in the Pulmonary Region
In order to further investigate the localization and permanence of SLNas samples within the
pulmonary region, fluorescence microscopy on AM from BALF and lung tissue sections was performed.
Subsequently, RIF quantification in both AM and lung tissue was investigated. Once nanoparticles are
deposited onto the alveolar region of the respiratory tract, they first come into contact with pulmonary
surfactant and then they are taken up by AM mostly within 2–3 h after particle deposition [19].
Hence, BALF was isolated in order to remove non-internalized nanoparticles from the lungs and
collect non-adherent AM, i.e., the cells residing in the airway lumen and representing more than
90% of the cells contained in the mouse BALF [38–40]. As a further result, non-adherent AM were
separated from interstitial macrophages, a large component of the total macrophage population
in murine lungs residing in lung parenchyma [41]. AM recovery from BALF, however, has been
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reported to be incomplete since the most activated AM by particle internalization strongly adhere
to the lung tissue [41,42]. The morphologic study of BALF cell population by optical microscopy
observation confirmed that the majority of cells were AM. No significant differences in the total number
of macrophages collected in BALF were observed among the administered SLNas samples as well as in
comparison with that obtained from the untreated mice, regardless of the collection time. Compared
with the control (cells from untreated mice), IR-780 particle-related fluorescence was observed in
the collected AM for SLNas/MS, SLNas/MS-ST, and SLNas/ST both at 0.5 h and 3 h post-exposure
(Figure 4). This finding might already evidence the AM internalization of the mannosylated samples
as well as SLNas bearing ST on their surface, nearly in agreement with previous in vitro results [17]. In
contrast, negligible fluorescence intensities were detected for SLNas/F127, regardless of the collection
time. Cell internalization appears, therefore, to be precluded in the case of SLNas/F127 as support of
its insufficient respirability properties [17] and the known cell adhesion inhibition ascribed to F127
chains [43].
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Figure 4. Fluorescence microscopy on AM from BALF showing SLNas post-exposure. Pictures were
taken with a 40× magnification. From left to right, first frame: image taken using the filter for Hoechst
staining (cells); second frame: image taken using the filter for IR-780 (SLNas); third frame: merge,
showing BALF AM in blue and IR-780/SLNas in red. Animals were euthanized after 0.5 (right panel)
and 3 h (left panel) post-exposure and BALF was immediately collected for analysis. Scale bars =
25 µm.
Lung dissections at 24 h post-exposure observed by fluorescence microscopy indicated that
a portion of SLNas was still present in the lung tissue, regardless of SLNas sample (Figure S1),
in agreement with FMT results. In the early post-exposure time points (0.5 and 3 h), the relationship
between SLNas detected within AM by means of fluorescence microscopy and RIF quantification in
the lungs might offer information about nanoparticle entry mechanisms according to their surface
properties. The highest RIF levels in lungs (p < 0.001) were found following SLNas/MS administration
(19.65 ± 10.97% and 2.36 ± 2.65% of the inhaled dose per gram of tissue at 0.5 and 3 h, respectively).
Otherwise, RIF levels were about 10-fold lower following 0.5 h exposure to SLNas/MS-ST and SLNas/ST
(1.87 ± 1.97% and 2.35 ± 2.41% of the inhaled dose per gram of tissue, respectively) and about 4.5-fold
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lower for bare RIF (4.37 ± 3.30% of the inhaled dose per gram of tissue) without significant differences
among them (p > 0.05). Then, RIF levels declined up to the quantification limit or to negligible
concentrations at 3 h post-exposure (Figure 5). Only SLNas/MS provided RIF levels higher than the
minimum inhibitory concentration against Mtb strain [30] regardless of the post-exposure time.
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Figure 5. Quantification of RIF in plasma and tissue homogenates. Percentages of RIF dose per
plasma volume or lung, liver, and kidneys weight (n = 4–6) at 0.5 h (A) and 3 h (B) after intratracheal
administration of SLNas/MS, SLNas/MS-ST, SLNas/ST, SLNas/F127, and bare RIF. ***§ p < 0.001 vs.
SLNas/MS-ST, SLNas/ST, SLNas/F127, and bare RIF. ***# p < 0.001 vs. SLNas/MS-ST, SLNas/ST,
SLNas/F127 and bare RIF. * p < 0.05 vs. SLNas/MS-ST.
The greater RIF retention in the lungs measured at 0.5 h post-exposure to SLNas/MS might
have received the major contribution from internalization by adherent AM via the mannose-receptor
mediated pathway in accordance with the results obtained previously on murine MH-S cells [17].
Although SLNas/MS-ST and SLNas/ST were detected within AM as well, the lower immediate retention
of RIF in lungs compared with that achieved by SLNas/MS administration could be related to their
passive mechanism of entry AM without mannose receptor involvement [17]. Despite this, the role
of the carrier surfaces modified by MS in a blend with ST as well as ST alone would ensure a certain
intramacrophagic activity in contrast to the inhalation of bare RIF. Indeed, drug localization in lungs
post-exposure to bare RIF, showing difficulty of crossing AM membrane as demonstrated previously [6],
could be reasonably assigned to a translocation mechanism across epithelial cells into the interstitium
or other lung cells. Declining RIF concentrations at 3 h post-exposure was observed for all the groups.
The decrease of RIF levels could be attributed to both AM clearance involving RIF biodegradation [6]
and systemic translocation. Other pathways for lung entrance and subsequent clearance should be,
however, considered for SLNas bearing ST on their surface. In fact, in addition to AM internalization,
the paracellular passage should be feasible owing to the well-known permeation enhancing properties
of ST [44]. Otherwise, drug lung clearance following 3 h post-exposure to bare RIF might be due to the
molecule absorption beyond the epithelial barrier into the blood and lymphatic circulation. No RIF
amounts, conversely, were measured in the lungs at both 0.5 and 3 h post-exposure to SLNas/F127
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in agreement with the lack of AM fluorescence and RIF levels determined previously on MH-S cell
line [17]. This finding is consistent with the non-adhering properties of F127 surfactant to cells,
preventing nanoparticle translocation across both AM and epithelial cells. No RIF was detected within
non-adherent AM collected from the BALF post-exposure to all the samples, regardless of the exposure
time probably owing to the quantification limit of the HPLC method.
From a histopathological point of view, lung sections examined at 24 h post-exposure to SLNas/ST,
SLNas/MS-ST, and SLNas/F127 samples indicated the absence of an inflammatory response. No signs
of toxicity were expected, since all the samples were obtained by using recognized biocompatible
excipients [45]. Moreover, in vivo administration of RIF in rats did not exhibited any evidence of
toxicity after inhalation [46]. On the contrary, a mild neutrophilic infiltration in mice treated with
SLNas/MS was noticed (Figure 6) even if MR activation has been generally recognized as a promoter of
the anti-inflammatory response [47–49]. Thus, a contribution to the inflammation might arise from the
increased SLNas/MS endocytosis compared with the other samples, leading to a higher production of
reactive oxygen species [50].
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Figure 6. Histological sections of the medial (left panel) and inferior portion (right panel) of control
mice lungs in comparison with lungs at 24 h post-exposure to SLNas/MS, SLNas/MS-ST, SLNas/ST,
and SLNas/F127. Arrows indicate mild neutrophilic infiltration. Slides were stained using H&E.
Magnification: 20×. Scale bars = 80 µm.
3.2.3. SLNas Biodistribution in Extra-Pulmonary Regions
Inhaled nanoparticles have been proved to pass through the lung epithelium, enter the blood
circulation, and accumulate in extra-pulmonary organs, mainly according to the nanoparticle size [21].
Translocation from the lungs to other organs with a possible accumulation in lymph nodes may occur
from direct uptake into epithelial cells and/or phagocytosis by AM, which then migrate into the lung
interstitium [26,51]. Thus, plasma, liver, and kidneys were analyzed by both RIF quantification at 0.5
and 3 h post-exposure to SLNas samples and bare RIF as well as FMT at 0.5, 3, 6, and 24 h post-exposure
to SLNas samples. However, regarding the recovery of RIF in plasma, RIF serum half-life in mice
(about 5 h) needs to be taken into account [52,53]. In addition, plasma levels are transient since they are
balanced with the clearance by the kidneys and uptake by the other tissues. Drug levels in plasma and
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liver were found less than 2% for all the samples, regardless of the exposure time, without significant
differences among them (p > 0.05). These findings indicate the poor systemic activity offered by the
lipid nanocarrier, irrespective of the pathway followed from the airway lumen into the lung tissue.
Similarly, other studies in mice have evidenced negligible levels in blood and extra-pulmonary organs
for nanoparticles >30 nm in size [18,21,26]. Drug levels in kidneys were barely measurable, regardless
of the sample and the exposure time (Figure 5).
4. Conclusions
The present in vivo study was addressed to assess the fate of rifampicin transported by
respirable mannosylated lipid-based nanoparticles designed for an intramacrophagic delivery. The
results highlighted the suitability of the RIF-loaded nanocarrier for efficiently targeting the alveolar
macrophages via a mannose-receptor mediated pathway with a poor systemic biodistribution. The
achievement of antimicrobial drug concentrations at this site of infection may support the goal of a
potential application as inhaled therapy for the treatment of the pulmonary tuberculosis.
Supplementary Materials: The following is available online at http://www.mdpi.com/2079-4991/10/3/568/s1,
Figure S1: Representative fluorescence microscopy images of lung dissections at 24 h post-exposure. Pictures
were taken with a 20× magnification. From left to right, first frame: images taken using the filter for Hoechst label
(cells), second frame: images taken using the filter for IR-780 label (SLNas), third frame: merge, showing lungs
cells in blue and SLNas in red. Scale bars = 100 µm.
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